{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:51:21Z","timestamp":1791089481272,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1245\/s10434-020-08650-z","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T12:06:12Z","timestamp":1591099572000},"page":"4515-4522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy"],"prefix":"10.1245","volume":"27","author":[{"given":"Giacomo","family":"Montagna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Knezevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edi","family":"Brogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea V.","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"issue":"6","key":"8650_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrclinonc.2015.63","volume":"12","author":"TA King","year":"2015","unstructured":"King TA, Morrow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol. 2015;12(6):335\u201343.","journal-title":"Nat Rev Clin Oncol."},{"issue":"8","key":"8650_CR2","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1245\/s10434-018-6531-5","volume":"25","author":"BL Murphy","year":"2018","unstructured":"Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2+\u2009subtypes. Ann Surg Oncol. 2018;25(8):2241\u201348.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"8650_CR3","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","volume":"23","author":"A Mamtani","year":"2016","unstructured":"Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;23(11):3467\u201374.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"8650_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaoncol.2015.4919","volume":"2","author":"M Morrow","year":"2016","unstructured":"Morrow M. Parsing pathologic complete response in patients receiving neoadjuvant chemotherapy for breast cancer. JAMA Oncol. 2016;2(4):516\u20137.","journal-title":"JAMA Oncol."},{"issue":"11","key":"8650_CR5","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1245\/s10434-016-5277-1","volume":"23","author":"J Vila","year":"2016","unstructured":"Vila J, Mittendorf EA, Farante G, et al. Nomograms for predicting axillary response to neoadjuvant chemotherapy in clinically node-positive patients with breast cancer. Ann Surg Oncol. 2016;23(11):3501\u201309.","journal-title":"Ann Surg Oncol."},{"issue":"36","key":"8650_CR6","doi-asserted-by":"publisher","first-page":"9304","DOI":"10.1200\/JCO.2005.02.5023","volume":"23","author":"BT Hennessy","year":"2005","unstructured":"Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23(36):9304\u201311.","journal-title":"J Clin Oncol."},{"issue":"12","key":"8650_CR7","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1002\/cncr.25152","volume":"116","author":"LS Dominici","year":"2010","unstructured":"Dominici LS, Negron Gonzalez VM, Buzdar AU, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010;116(12):2884\u20139.","journal-title":"Cancer."},{"issue":"14","key":"8650_CR8","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361.","journal-title":"JAMA."},{"issue":"7","key":"8650_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609\u201318.","journal-title":"Lancet Oncol."},{"issue":"3","key":"8650_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258\u201364.","journal-title":"J Clin Oncol."},{"issue":"2","key":"8650_CR11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10549-018-5004-7","volume":"173","author":"JM Classe","year":"2019","unstructured":"Classe JM, Loaec C, Gimbergues P, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019;173(2):343\u201352.","journal-title":"Breast Cancer Res Treat."},{"issue":"12","key":"8650_CR12","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/bjs.10986","volume":"105","author":"SR Tee","year":"2018","unstructured":"Tee SR, Devane LA, Evoy D, et al. Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. Br J Surg. 2018;105(12):1541\u201352.","journal-title":"Br J Surg."},{"issue":"11","key":"8650_CR13","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1245\/s10434-019-07583-6","volume":"26","author":"SM Wong","year":"2019","unstructured":"Wong SM, Weiss A, Mittendorf EA, King TA, Golshan M. Surgical management of the axilla in clinically node-positive patients receiving neoadjuvant chemotherapy: a national cancer database analysis. Ann Surg Oncol. 2019;26(11):3517\u201325.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"8650_CR14","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1245\/s10434-017-5958-4","volume":"24","author":"AS Caudle","year":"2017","unstructured":"Caudle AS, Bedrosian I, Milton DR, et al. Use of sentinel lymph node dissection after neoadjuvant chemotherapy in patients with node-positive breast cancer at diagnosis: practice patterns of American Society of Breast Surgeons Members. Ann Surg Oncol. 2017;24(10):2925\u201334.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"8650_CR15","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1245\/s10434-018-6637-9","volume":"25","author":"TT Nguyen","year":"2018","unstructured":"Nguyen TT, Hoskin TL, Day CN, et al. Decreasing use of axillary dissection in node-positive breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25(9):2596\u2013602.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"8650_CR16","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.ejso.2019.01.219","volume":"45","author":"R Di Micco","year":"2019","unstructured":"Di Micco R, Zuber V, Fiacco E, et al. Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: time trend, imaging staging power and nodal downstaging according to molecular subtype. Eur J Surg Oncol. 2019;45(6):969\u201375.","journal-title":"Eur J Surg Oncol."},{"issue":"12","key":"8650_CR17","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1245\/s10434-019-07515-4","volume":"26","author":"A Laws","year":"2019","unstructured":"Laws A, Hughes ME, Hu J, et al. Impact of residual nodal disease burden on technical outcomes of sentinel lymph node biopsy for node-positive (cN1) breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2019;26(12):3846\u201355.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"8650_CR18","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S1072-7515(01)00847-X","volume":"192","author":"MD McCarter","year":"2001","unstructured":"McCarter MD, Yeung H, Fey J, Borgen PI, Cody HS, 3rd. The breast cancer patient with multiple sentinel nodes: when to stop? J Am Coll Surg. 2001;192(6):692\u201397.","journal-title":"J Am Coll Surg."},{"issue":"8","key":"8650_CR19","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/cncr.24964","volume":"116","author":"ER Port","year":"2010","unstructured":"Port ER, Patil S, Stempel M, Morrow M, Cody HS, 3rd. Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size: a new source of bias in morbidity assessment? Cancer. 2010;116(8):1987\u201391.","journal-title":"Cancer."},{"issue":"2","key":"8650_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1245\/s10434-018-7004-6","volume":"26","author":"JL Baker","year":"2019","unstructured":"Baker JL, Muhsen S, Zabor EC, Stempel M, Gemignani ML. Does lymph node status prior to neoadjuvant chemotherapy influence the number of sentinel nodes removed? Ann Surg Oncol. 2019;26(2):336\u201342.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"8650_CR21","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S0039-6060(99)70127-3","volume":"126","author":"M Morrow","year":"1999","unstructured":"Morrow M, Rademaker AW, Bethke KP, et al. Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery. 1999;126(4):714\u201320; discussion 720\u2013712.","journal-title":"Surgery."},{"issue":"2","key":"8650_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1046\/j.1524-4741.2002.08203.x","volume":"8","author":"CE Cox","year":"2002","unstructured":"Cox CE, Dupont E, Whitehead GF, et al. Age and body mass index may increase the chance of failure in sentinel lymph node biopsy for women with breast cancer. Breast J. 2002;8(2):88\u201391.","journal-title":"Breast J."},{"issue":"4","key":"8650_CR23","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1245\/s10434-009-0331-x","volume":"16","author":"CR Schmidt","year":"2009","unstructured":"Schmidt CR, Panageas KS, Coit DG, Patel A, Brady MS. An increased number of sentinel lymph nodes is associated with advanced Breslow depth and lymphovascular invasion in patients with primary melanoma. Ann Surg Oncol. 2009;16(4):948\u201352.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"8650_CR24","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/SLA.0000000000001375","volume":"263","author":"JC Boughey","year":"2016","unstructured":"Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0\u2013T4, N1\u2013N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263(4):802\u201307.","journal-title":"Ann Surg."},{"issue":"10","key":"8650_CR25","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072\u201378.","journal-title":"J Clin Oncol."},{"issue":"9","key":"8650_CR26","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.ejso.2018.05.035","volume":"44","author":"S Hartmann","year":"2018","unstructured":"Hartmann S, Reimer T, Gerber B, Stubert J, Stengel B, Stachs A. Wire localization of clip-marked axillary lymph nodes in breast cancer patients treated with primary systemic therapy. Eur J Surg Oncol. 2018;44(9):1307\u201311.","journal-title":"Eur J Surg Oncol."},{"issue":"13","key":"8650_CR27","doi-asserted-by":"publisher","first-page":"4241","DOI":"10.1245\/s10434-015-4527-y","volume":"22","author":"D Plecha","year":"2015","unstructured":"Plecha D, Bai S, Patterson H, Thompson C, Shenk R. Improving the accuracy of axillary lymph node surgery in breast cancer with ultrasound-guided wire localization of biopsy proven metastatic lymph nodes. Ann Surg Oncol. 2015;22(13):4241\u201346.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"8650_CR28","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1245\/s10434-017-6023-z","volume":"24","author":"TT Nguyen","year":"2017","unstructured":"Nguyen TT, Hieken TJ, Glazebrook KN, Boughey JC. Localizing the clipped node in patients with node-positive breast cancer treated with neoadjuvant chemotherapy: early learning experience and challenges. Ann Surg Oncol. 2017;24(10):3011\u201316.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"8650_CR29","first-page":"941","volume":"12","author":"S Sharifi","year":"1999","unstructured":"Sharifi S, Peterson MK, Baum JK, Raza S, Schnitt SJ. Assessment of pathologic prognostic factors in breast core needle biopsies. Mod Pathol. 1999;12(10):941\u201345.","journal-title":"Mod Pathol."},{"issue":"4","key":"8650_CR30","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/SLA.0000000000000924","volume":"260","author":"JC Boughey","year":"2014","unstructured":"Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014;260(4):608\u201314; discussion 614\u2013606.","journal-title":"Ann Surg."},{"issue":"1","key":"8650_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25\u201332.","journal-title":"Lancet Oncol."},{"issue":"3","key":"8650_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.anndiagpath.2009.02.003","volume":"13","author":"I Alvarado-Cabrero","year":"2009","unstructured":"Alvarado-Cabrero I, Alderete-Vazquez G, Quintal-Ramirez M, Patino M, Ruiz E. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2\/Neu, and gross pathologic findings. Ann Diagn Pathol. 2009;13(3):151\u201357.","journal-title":"Ann Diagn Pathol."},{"issue":"2","key":"8650_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/1066896907307047","volume":"16","author":"L Chen","year":"2008","unstructured":"Chen L, Fan Y, Lang RG, et al. Breast carcinoma with micropapillary features: clinicopathologic study and long-term follow-up of 100 cases. Int J Surg Pathol. 2008;16(2):155\u201363.","journal-title":"Int J Surg Pathol."},{"issue":"5","key":"8650_CR34","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1200\/JCO.19.01304","volume":"38","author":"JK Litton","year":"2020","unstructured":"Litton JK, Scoggins ME, Hess KR, et al. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol. 2020;38(5):388\u201394.","journal-title":"J Clin Oncol."},{"issue":"11","key":"8650_CR35","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1245\/s10434-016-5296-y","volume":"23","author":"E Mamounas","year":"2016","unstructured":"Mamounas E, Poulos C, Goertz HP, Gonzalez JM, Pugh A, Antao V. Neoadjuvant systemic therapy for breast cancer: factors influencing surgeons\u2019 referrals. Ann Surg Oncol. 2016;23(11):3510\u201317.","journal-title":"Ann Surg Oncol."},{"key":"8650_CR36","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (Breast Cancer) Version 3.2020, 6 Mar 2020."},{"issue":"10","key":"8650_CR37","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","volume":"30","author":"HJ Burstein","year":"2019","unstructured":"Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541\u201357.","journal-title":"Ann Oncol."},{"issue":"8","key":"8650_CR38","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30(8):1194\u2013220.","journal-title":"Ann Oncol."},{"issue":"3","key":"8650_CR39","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ejso.2015.11.019","volume":"42","author":"V Galimberti","year":"2016","unstructured":"Galimberti V, Ribeiro Fontana SK, Maisonneuve P, et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol. 2016;42(3):361\u201368.","journal-title":"Eur J Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08650-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-08650-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08650-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T19:32:05Z","timestamp":1622575925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-08650-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["8650"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-08650-z","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,2]]},"assertion":[{"value":"23 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The preparation of this manuscript was supported in part by NIH\/NCI Cancer Center Support Grant No. P30 CA008748 to Memorial Sloan Kettering Cancer Center. Dr. Monica Morrow has received speaking honoraria from Genomic Health, and Dr. Andrea V. Barrio has received speaking honoraria from Roche. Dr. Giacomo Montagna was supported by the Ticino Cancer League, the Hanne Liebermann Foundation, the Fondation Ancrage, and the HEMMI-Stiftung. Anita Mamtani, Andrea Knezevic, and Edi Brogi have no conflicts of interest to report. This study has been accepted for presentation in poster format at the Society of Surgical Oncology 2020 International Conference on Surgical Cancer Care.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}